Effects of two novel nucleoside analogues on different hepatitis B virus promoters

Table 1 Primer sequences used for PCR

Target	Primer sequences	Product size (bp)
preSp	F5’-GACAAAggtaccAAACCATATTATCC-3’	229
	R5’-GAGGAccggtAACAGAAAGATTCGT-3’
Sp	F5’-GATTGgtaccTCAACCCCAACAAG-3’	458
	R5’-GAAAAAccggtCCTGTAACACGAG-3’
Cp	F5’-CCACCggtaccTGCCCAAGGTCTTA-3’	302
	R5’-TCCAAAccggtTATACGGGTCAATG-3’
Xp	F5’-GTATggtaccGAATTGTGGGTCTTTTG-3’	445
	R5’-ACGTAAACAccggtCGTCCCGCGC-3’

Table 2 Effect-dosage relationship of the inhibition of the expression of EGFP under the control of the Sp and Xp promoters by β-L-D4A

Dosage (&mgr;mol/L)	n	EGFP-positive cells (%) (mean ± SD)		Inhibition rate (%)
		Sp	Xp	Sp	Xp
Control	3	21.26 ± 0.25	18.52 ± 1.25	0.0	0.0
(Lamivudine)	4	21.00 ± 0.43	18.37 ± 1.01	1.2	0.8
0.08	4	18.76 ± 0.41b	16.47 ± 0.49b	11.8	11.1
0.4	4	17.31 ± 0.41b	15.68 ± 0.36b	18.6	15.3
2	4	15.54 ± 0.48b	13.54 ± 0.59b	26.9	26.9
10	4	11.33 ± 0.32b	10.84 ± 0.81b	46.7	41.5

^bP < 0.01 vs Blank control. EGFP: Enhanced green fluorescent protein.

Table 3 Effect-dosage relationship of the inhibition of the expression of EGFP under the control of the Cp and Xp promoters by β-LPA

Dosage (&mgr;mol/L)	n	EGFP-positive cells (%) (mean ± SD)		Inhibition rate (%)
		Cp	Xp	Cp	Xp
Control	3	13.99 ± 0.29	18.58 ± 0.39	0.0	0.0
(Lamivudine)	4	13.80 ± 0.63	18.46 ± 0.49	1.3	0.6
0.002	4	12.98 ± 0.16b	17.54 ± 0.31b	7.2	5.6
0.01	4	11.96 ± 0.75b	16.18 ± 0.21b	14.5	12.9
0.05	4	10.88 ± 0.43b	14.63 ± 0.37b	22.2	21.3
1	4	8.79 ± 0.56b	11.94 ± 1.37b	37.7	35.7

^bP < 0.01 vs Blank control. EGFP: Enhanced green fluorescent protein.